Failed PhIIIs after a rejection by the FDA spur Sanofi to dump its $1.7B deal with Lexicon on diabetes drug — shares crash
Sanofi’s nearly 4-year-old quest to ride Lexicon’s SGLT1/2 diabetes drug sotagliflozin to a last place finish in the field ended with an abrupt exit Friday in a statement posted after the bell.
The pharma giant noted uncomfortably mixed data on 3 Phase III trials, with a hit on a statistically significant reduction in HbA1c for Type 2 patients on metformin, compared to placebo, followed by a fail for diabetics after 26 weeks in patients with CKD4 and a mixed result in a third study, with a failure for a key subpopulation with stage 3B CKD4.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,100+ biopharma pros reading Endpoints daily — and it's free.